9 Best Rising Penny Stocks to Buy According to Wall Street Analysts
On June 27, Jefferies’ DeSanctis appeared on a CNBC Television interview to discuss what’s next for small-cap stocks.
C4 Therapeutics Inc. (CCCC)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 8,000,000 | $21,040,000 | 0.22% | |
| 2. | Lynx1 Capital Management Weston Nichols | 6,998,902 | $18,407,112 | -2% | 2.91% |
| 3. | Soleus Capital Guy Levy | 3,803,942 | $10,004,367 | 0.41% | |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 3,035,634 | $7,983,717 | +185% | 0.01% |
| 5. | Citadel Investment Group Ken Griffin | 2,511,015 | $6,603,969 | +461% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.60 | 5,667 | $31,735.20 | 5,667 | 2023-02-08 | Filing | |
| $8.40 | 10,000 | $84,000.00 | 10,000 | 2022-04-12 | Filing | |
| $19.00 | 5,263 | $99,997.00 | 5,263 | 2020-10-06 | Filing | |
| $19.00 | 5,030 | $95,570.00 | 5,030 | 2020-10-06 | Filing | |
| $19.00 | 1,315 | $24,985.00 | 15,994 | 2020-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.22 | 10,000 | $22,200.00 | 156,382 | 2026-01-16 | Filing | |
| $3.15 | 669 | $2,107.35 | 107,805 | 2025-02-18 | Filing | |
| $3.15 | 490 | $1,543.50 | 110,842 | 2025-02-14 | Filing | |
| $32.66 | 1,054 | $34,420.48 | 15,000 | 2022-01-04 | Filing | |
| $31.59 | 13,946 | $440,547.17 | 16,054 | 2022-01-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,522,644 | $16,450,747 | 0.11% | |
| 2. | 1,003,437 | $4,686,051 | 0.03% | |
| 3. | 14,129 | $65,982 | 0.01% | |
| 4. | 0 | $0 | 0% |
News See All
Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock
C4 Therapeutics, Inc. (NASDAQ:CCCC) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. According to CNN’s compilation of price targets, all 8 analysts covering C4 Therapeutics, Inc.
10 Best High-Risk Penny Stocks to Buy Right Now
On March 17, a report published by Royce Investment Partners highlighted an interesting aspect of the performance of microcap stocks.
C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data
C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the 11 most popular AI penny stocks to buy now. On February 23, Brookline increased the firm’s price target on C4 Therapeutics Inc.
11 Most Popular AI Penny Stocks to Buy Now
The need for the adoption of Artificial Intelligence (AI) is becoming increasingly pivotal for businesses to elevate their operations.
Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential
As of February 16, 2026, all of the analysts who cover C4 Therapeutics, Inc. (NASDAQ:CCCC) remain bullish on the stock.
7 Most Volatile Stocks Under $5 for Day Trading
Morningstar released its Q1 2026 U.S. Stock Market Outlook report last month. Led by Chief U.S. Economist Preston Caldwell and Chief U.S.
C4 Therapeutics, Inc. (CCCC): A Bull Case Theory
We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC.
Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts?
C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the best biotech penny stocks to buy according to analysts.
12 Best Biotech Penny Stocks To Invest In Now
Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from lower borrowing costs: biotechnology stocks.
Hedge Fund Resource Center